The Priority Review

Approvals Brief

CHMP adopts positive opinion on Baxfendy

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB.

Primary source

EMA medicine page (CHMP opinion), November 13, 2026

Baxfendy (baxdrostat): EMA CHMP opinion

Read the source ema.europa.eu

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation